Back to Results

Alto Neuroscience Inc (ANRO)

Featured in Overvalued Stocks High-Beta Stocks Small-Cap Stocks

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company listed on the NYSE under the ticker ANRO. Headquartered in Mountain View, California, the company was incorporated in 2019 and focuses on developing therapies for central nervous system and neuropsychiatric conditions. Its pipeline includes ALTO-100, which is in a Phase 2b trial for bipolar depression; ALTO-300, a small-molecule melatonergic agonist and serotonergic antagonist in Phase 2b testing for major depressive disorder; and ALTO-101, a phosphodiesterase 4 inhibitor in Phase 2 proof-of-concept studies for cognitive impairment associated with schizophrenia. The company is also advancing ALTO-203 for major depressive disorder with higher levels of anhedonia, ALTO-202 for major depressive disorder, and ALTO-208 for patients with Parkinson’s disease.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NYSE-ANRO
$20.36
-23.9% Downside
Overvalued
$35.13
31.2% Upside
Undervalued
Good
—
—
—
0.0%
August 19, 2026
-14.1x
4.3x
—
1.007 B
809 M
2.3%
70.6%
17.4
—
84.6%
Send a message
Valuation • Fair Value

Alto Neuroscience Inc (NYSE-ANRO) Fair Value by Valuation Model

Compare the primary fair value estimate for Alto Neuroscience Inc (NYSE-ANRO) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$20.36

Estimated downside of 23.9% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

$16.99

Discounted cash flow valuation reference.

Ben Graham Formula Value

$0

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

NM

Earnings power value estimate.

Comps Fair Value

$22.05

Comparable-company valuation reference.

Analyst Price Target

$35.13

Analysts imply upside of 31.2%.

How to read these valuation models

Use this section to compare the primary fair value estimate for Alto Neuroscience Inc (NYSE-ANRO) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Alto Neuroscience Inc (NYSE-ANRO)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

Not available

Data is currently unavailable.

Revenue Forecast

0 K

Forward revenue estimate.

EBITDA

-77.152 M

Current operating profitability reference.

EBITDA Forecast

-108.6 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Alto Neuroscience Inc (NYSE-ANRO) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Alto Neuroscience Inc (NYSE-ANRO)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Good

Positive financial-health read.

Piotroski Score

3

Weak quality score that deserves closer review.

Beneish M-Score

NM

Forensic accounting screen.

Altman Z-Score

17.4

Relatively strong balance-sheet zone.

FCF / Net Income

84.6%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Alto Neuroscience Inc (NYSE-ANRO). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Alto Neuroscience Inc (NYSE-ANRO)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

August 19, 2026

Days to Earnings

29

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for Alto Neuroscience Inc (NYSE-ANRO), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Alto Neuroscience Inc (NYSE-ANRO) Stock Forecast & Technical Outlook

Review Alto Neuroscience Inc (NYSE-ANRO) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Neutral

The 15-minute technical read for Alto Neuroscience Inc (NYSE-ANRO) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Neutral

The 1-hour technical read for Alto Neuroscience Inc (NYSE-ANRO) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Buy

The daily technical read for Alto Neuroscience Inc (NYSE-ANRO) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for Alto Neuroscience Inc (NYSE-ANRO) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Buy

The monthly technical read for Alto Neuroscience Inc (NYSE-ANRO) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Alto Neuroscience Inc (NYSE-ANRO)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Alto Neuroscience Inc (NYSE-ANRO) has a Strong Buy consensus, with 11 buy, 1 hold and 0 sell recommendations in the current data set.

Buy 11
Hold 1
Sell 0
FAQ • Fast Investor Answers

Alto Neuroscience Inc (NYSE-ANRO) Stock FAQ

Quick answers about Alto Neuroscience Inc (NYSE-ANRO) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$20.36
Estimated downside 23.9%
Valuation Rating
Overvalued
Estimated downside of 23.9%
Analyst Target
$35.13
Implied upside 31.2%
Financial Health
Good
Current financial-health read

The current fair value estimate for Alto Neuroscience Inc (NYSE-ANRO) is $20.36. This implies an estimated downside of 23.9% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 23.9% versus the current market price.

The available analyst price target for Alto Neuroscience Inc (NYSE-ANRO) is $35.13. The analyst target implies estimated upside of 31.2%.

The current financial health read for Alto Neuroscience Inc (NYSE-ANRO) is Good. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Alto Neuroscience Inc (NYSE-ANRO) is August 19, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for Alto Neuroscience Inc (NYSE-ANRO) is -14.1x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Alto Neuroscience Inc is 1.007 B.

The current enterprise value listed for Alto Neuroscience Inc is 809 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Alto Neuroscience Inc is NYSE-ANRO, and the stock is listed on NYSE.

Alto Neuroscience Inc (NYSE-ANRO) is listed on NYSE.

The current debt-to-total-capital ratio listed for Alto Neuroscience Inc is 2.3%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Alto Neuroscience Inc is 70.6%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks on NYSE View more

Eli Lilly and Company (LLY) Eli Lilly and Company (LLY)
Johnson & Johnson (JNJ) Johnson & Johnson (JNJ)
Merck & Company Inc (MRK) Merck & Company Inc (MRK)
Novartis AG ADR (NVS) Novartis AG ADR (NVS)
Novo Nordisk A/S (NVO) Novo Nordisk A/S (NVO)
Pfizer Inc (PFE) Pfizer Inc (PFE)
Bristol-Myers Squibb Company (BMY) Bristol-Myers Squibb Company (BMY)
GSK plc DRC (GSK) GSK plc DRC (GSK)
Takeda Pharmaceutical Co Ltd ADR (TAK) Takeda Pharmaceutical Co Ltd ADR (TAK)
HALEON PLC ADR (HLN) HALEON PLC ADR (HLN)
Teva Pharma Industries Ltd ADR (TEVA) Teva Pharma Industries Ltd ADR (TEVA)
Zoetis Inc (ZTS) Zoetis Inc (ZTS)
Elanco Animal Health (ELAN) Elanco Animal Health (ELAN)
Dr. Reddy’s Laboratories Ltd ADR (RDY) Dr. Reddy’s Laboratories Ltd ADR (RDY)
Veradermics Inc (MANE) Veradermics Inc (MANE)
Organon & Co (OGN) Organon & Co (OGN)
Prestige Consumer Healthcare Inc (PBH) Prestige Consumer Healthcare Inc (PBH)
Nuvation Bio Inc (NUVB) Nuvation Bio Inc (NUVB)
Bausch Health Companies Inc (BHC) Bausch Health Companies Inc (BHC)
Perrigo Company PLC (PRGO) Perrigo Company PLC (PRGO)
Rafael Holdings Inc Class B (RFL) Rafael Holdings Inc Class B (RFL)
Impact Biomedical Inc (IBO) Impact Biomedical Inc (IBO)
China Pharma Holdings Inc (CPHI) China Pharma Holdings Inc (CPHI)
Nasus Pharma Ltd (NSRX) Nasus Pharma Ltd (NSRX)